Skip to content
Changing a Treatment Landscape by De-Risking Drug Development episode artwork

Nov 13, 2025 28 min

Changing a Treatment Landscape by De-Risking Drug Development

from RARECast

Spinocerebellar ataxia is a group of inherited, heterogeneous neurodegenerative diseases affecting coordination, speech, and vision. There are currently no FDA approved therapies for the more than 50 known types of SCA​, but there is a growing pipeline of therapeutic candidates. We spoke to Andrew Rosen, CEO of the National Ataxia Foundation, about the challenges of developing therapies for spinocerebellar ataxia, the critical role of patient-led organizations in early-stage research and advocacy, and the recent surge of therapeutic activity targeting these neurodegenerative conditions.

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Changing a Treatment Landscape by De-Risking Drug Development

0:00 28:08

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of RARECast?

This episode is 28 minutes long.

When was this RARECast episode published?

This episode was published on November 13, 2025.

Can I download this RARECast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.